Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...

Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. The strong market debut of ...

Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

Metsera, Inc. (Nasdaq: MTSR) ("Metsera"), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...

Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...

Blackstone joins other big investors such as ARCH Venture Partners and Bain Capital Life Sciences in pumping billions of ...

The IPO comes amid a deregulatory push in the energy sector by President Donald Trump, who repeated the "drill, baby, drill" slogan in his inaugural address. Earlier this week, Sean Duffy, the newly ...